Extended Data Fig. 3: Overview of lipidomics data in the heart tissues from HCM patients, related to Fig. 3.
From: Metabolic characterization of hypertrophic cardiomyopathy in human heart
a, PLS-DA score plot of lipidomics data on HCM patients and non-HCM controls (Ctrl). b-d, Volcano plots of sphingolipids (b), glycerophospholipids (c) and neutral lipids (d) alterations between HCM and non-HCM controls. Significantly upregulated, downregulated (FDR-corrected P value < 0.05, fold change > 1.5 or < 0.67) and unchanged metabolites were colored in red, blue, and gray, respectively. Top 10 most significantly increased or decreased metabolites of fold change in each group are labeled. The horizontal line denotes a FDR cutoff of 0.05, and the vertical lines denote a fold change of 1.5 or 0.67. e, Relative intensity of PG, PI and PS in HCM (n = 349) and non-HCM controls (n = 16). The box plots visualized as median and 25th and 75th percentiles, with whiskers indicating maximal and minimal values. f, Fold change of TAG with different numbers of carbon between HCM and non-HCM controls. Statistical analyses were performed by two-sided Mann–Whitney U-test (e) and followed by Benjamini–Hochberg correction (b-d).
